CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 755 enrolled
Drug / intervention
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg +2 moredrug
Likely dose
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04518306
NCT04518306Phase 3Completed

Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension

George Medicines PTY Limited·interventional·Posted Aug 19, 2020·Updated Jun 3, 2025

In Brief

A Phase 3 clinical trial evaluating Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, and 1 other intervention for Hypertension. Completed, enrolled 755 participants across 47 sites in 5 countries.

Detailed Summary

Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesAustralia, Nigeria, Sri Lanka, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedAug 19, 2020
Enrollment StartJun 14, 2021
Primary CompletionSep 19, 2023
Study CompletionOct 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.9 years ago

Interventions

Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mgdrug

Oral tablets

Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mgdrug

Oral tablets

Placebodrug

Placebo